FIGURE

Figure 6

ID
ZDB-FIG-240606-42
Publication
Pan et al., 2024 - Creatine and L-carnitine attenuate muscular laminopathy in the LMNA mutation transgenic zebrafish
Other Figures
All Figure Page
Back to All Figure Page
Figure 6

The muscle endurance of 1-month-old F2 heterozygous LMNA transgenic zebrafish after treated with chemicals. (A) Muscle endurance of AB(WT): n = 8; LMNA(L35P): n = 5; LMNA(L35P) + l-carnitine: n = 8. (B) Muscle endurance of AB(WT): n = 8; LMNA(R453W); n = 6; LMNA(R453W) + tyrosine: n = 8; LMNA(R453W) + taurine: n = 6; LMNA(R453W) + creatine: n = 7. (C) Muscle endurance of AB(WT): n = 9; LMNA(A539V): n = 7, LMNA(A539V) + l-carnitine: n = 7. Adult fish were treated with chemical for 1-month. Each dot represents one fish. Statistical analysis was conducted using a One-way ANONVA with Dunnett’s test, comparing the treated groups to either AB(WT) or the no drug treatment group. The presented p-values have been appropriately adjusted, and the level of statistical significance is indicated as following *represents 0.01 < P ≤ 0.05, **represents 0.001 < P ≤ 0.01, and ****represents P ≤ 0.0001. (D) Ingenuity Pathway Analysis (IPA) network pathway analysis revealed dysregulated genes in LMNA(R453W) mutant transgenic fish, resulting in decreased levels of creatine showing in blue. TGFB1 transforming growth factor-beta1, CCR2 C–C chemokine receptor type 2, C3 complement component 3, EDNRB endothelial receptor type B, CASP1 Caspase 1.

Expression Data

Expression Detail
Antibody Labeling
Phenotype Data
Fish:
Conditions:
Observed In:
Stage: Days 30-44

Phenotype Detail
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Sci. Rep.